NASDAQ, TSX: NVCN
VANCOUVER, June 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) a specialty medical device company today announced that Alexei Marko, chief executive officer is scheduled to present at the JMP Securities Life Sciences Conference being held at the St. Regis Hotel in New York City on Wednesday, June 21, 2017, at 9:30 am ET.
A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
VANCOUVER, June 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) a specialty medical device company today announced that Alexei Marko, chief executive officer is scheduled to present at the JMP Securities Life Sciences Conference being held at the St. Regis Hotel in New York City on Wednesday, June 21, 2017, at 9:30 am ET.
Advertisement
A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
